175 related articles for article (PubMed ID: 30551958)
1. Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Fanotto V; Fornaro L; Bordonaro R; Rosati G; Rimassa L; Di Donato S; Santini D; Tomasello G; Leone F; Silvestris N; Stragliotto S; Scartozzi M; Giampieri R; Nichetti F; Antonuzzo L; Cinieri S; Avallone A; Pellegrino A; Melisi D; Vasile E; Gerratana L; Aprile G
J Geriatr Oncol; 2019 Jul; 10(4):591-597. PubMed ID: 30551958
[TBL] [Abstract][Full Text] [Related]
2. Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment.
Turkmen E; Erdogan B; Kodaz H; Hacibekiroglu I; Onal Y; Uzunoglu S; Kilic N; Cicin I
Acta Gastroenterol Belg; 2016; 79(2):211-5. PubMed ID: 27382940
[TBL] [Abstract][Full Text] [Related]
3. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.
Turkeli M; Aldemir MN; Cayir K; Simsek M; Bilici M; Tekin SB; Yildirim N; Bilen N; Makas I
Asian Pac J Cancer Prev; 2015; 16(3):985-9. PubMed ID: 25735393
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.
Fanotto V; Uccello M; Pecora I; Rimassa L; Leone F; Rosati G; Santini D; Giampieri R; Di Donato S; Tomasello G; Silvestris N; Pietrantonio F; Battaglin F; Avallone A; Scartozzi M; Lutrino ES; Melisi D; Antonuzzo L; Pellegrino A; Ferrari L; Bordonaro R; Vivaldi C; Gerratana L; Bozzarelli S; Filippi R; Bilancia D; Russano M; Aprile G
Oncologist; 2017 Dec; 22(12):1463-1469. PubMed ID: 28860412
[TBL] [Abstract][Full Text] [Related]
6. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
7. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.
Hwang IG; Ji JH; Kang JH; Lee HR; Lee HY; Chi KC; Park SW; Lee SJ; Kim ST; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
J Geriatr Oncol; 2017 May; 8(3):170-175. PubMed ID: 28119041
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).
Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A;
Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world.
Fanotto V; Cordio S; Pasquini G; Fontanella C; Rimassa L; Leone F; Rosati G; Santini D; Giampieri R; Di Donato S; Tomasello G; Silvestris N; Pietrantonio F; Battaglin F; Avallone A; Scartozzi M; Lutrino ES; Melisi D; Antonuzzo L; Pellegrino A; Torri V; Aprile G
Gastric Cancer; 2017 Sep; 20(5):825-833. PubMed ID: 28028664
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study.
Choi IS; Choi M; Lee JH; Kim JH; Suh KJ; Lee JY; Kang B; Kim JW; Kim SH; Kim JW; Lee JO; Kim YJ; Bang SM; Lee JS; Lee KW
PLoS One; 2018; 13(6):e0198544. PubMed ID: 29879177
[TBL] [Abstract][Full Text] [Related]
11. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.
Hironaka S; Ueda S; Yasui H; Nishina T; Tsuda M; Tsumura T; Sugimoto N; Shimodaira H; Tokunaga S; Moriwaki T; Esaki T; Nagase M; Fujitani K; Yamaguchi K; Ura T; Hamamoto Y; Morita S; Okamoto I; Boku N; Hyodo I
J Clin Oncol; 2013 Dec; 31(35):4438-44. PubMed ID: 24190112
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.
Takashima A; Shitara K; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Kimura Y; Amagai K; Fujii H; Muro K; Esaki T; Choda Y; Takano T; Chin K; Sato A; Goto M; Fukushima N; Hara T; Machida N; Ohta M; Boku N; Shimura M; Morita S; Koizumi W
Gastric Cancer; 2019 Jan; 22(1):155-163. PubMed ID: 29855738
[TBL] [Abstract][Full Text] [Related]
13. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
[TBL] [Abstract][Full Text] [Related]
14. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
[TBL] [Abstract][Full Text] [Related]
15. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Bang YJ; Xu RH; Chin K; Lee KW; Park SH; Rha SY; Shen L; Qin S; Xu N; Im SA; Locker G; Rowe P; Shi X; Hodgson D; Liu YZ; Boku N
Lancet Oncol; 2017 Dec; 18(12):1637-1651. PubMed ID: 29103871
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
Li PJ; Mo HY; Luo DH; Hu WH; Jin T
Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
[TBL] [Abstract][Full Text] [Related]
17. Downstaging of lymph node metastasis after neoadjuvant intraperitoneal and systemic chemotherapy in gastric carcinoma with peritoneal metastasis.
Hao Y; Liu Y; Ishibashi H; Wakama S; Nishino E; Yonemura Y
Eur J Surg Oncol; 2019 Aug; 45(8):1493-1497. PubMed ID: 30948161
[TBL] [Abstract][Full Text] [Related]
18. Predictive and prognostic value of serum AFP level and its dynamic changes in advanced gastric cancer patients with elevated serum AFP.
Wang YK; Shen L; Jiao X; Zhang XT
World J Gastroenterol; 2018 Jan; 24(2):266-273. PubMed ID: 29375212
[TBL] [Abstract][Full Text] [Related]
19. Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes.
Nishimura T; Iwasa S; Nagashima K; Okita N; Takashima A; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Boku N
Gastric Cancer; 2017 Jul; 20(4):655-662. PubMed ID: 27858180
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis.
Visa L; Jiménez-Fonseca P; Martínez EA; Hernández R; Custodio A; Garrido M; Viudez A; Buxo E; Echavarria I; Cano JM; Macias I; Mangas M; de Castro EM; García T; Manceñido FÁ; Montes AF; Azkarate A; Longo F; Serrano AD; López C; Hurtado A; Cerdá P; Serrano R; Gil-Negrete A; Carnicero AM; Pimentel P; Ramchandani A; Carmona-Bayonas A;
J Geriatr Oncol; 2018 May; 9(3):254-264. PubMed ID: 29242093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]